

TABLE OF CONTENTS

Sr. No.	Titles	Page No.
Chapter 1 : Introduction		
1.1	Fungal Infection	1
1.1.1	Skin Fungal Infection	2
1.1.1.1	Prevalence	3
1.1.1.2	Signs and Symptoms	3
1.1.2	Nail Fungal Infections	4
1.1.2.1	Prevalence	4
1.2	Classification of drugs used for treatment of fungal infection	5
1.3	Luliconazole	6
1.4	Tavaborole	6
1.5	Topical Drug Delivery System	7
1.6	Nanoemulsion	7
1.7	Nanostructured lipid carriers (NLCs)	8
1.8	Hypothesis	9
1.9	Aim and Objectives	10
1.10	Plan of work	10
1.11	References	12
Chapter 2 :Literature Review		
2.1	Skin Fungal Infection	17
2.1.1	Etiology	18
2.1.2	Symptoms	18
2.1.3	Pathophysiology	18
2.1.4	Prevalence	19
2.2	Nail Fungal Infection	20
2.2.1	Etiology	20
2.2.2	Symptoms	20
2.2.3	Pathophysiology	21

2.2.4	Prevalence	21
2.3	Treatment of skin and nail fungal infection	22
2.3.1	Topical treatment	22
2.3.2	Oral Treatment	23
2.4	Luliconazole	24
2.4.1	Mechanism of action of Luliconazole	25
2.5	Tavaborole	28
2.5.1	Mechanism of action	29
2.6	Nanoemulsion in Topical drug delivery system	31
2.6.1	Formulation of Nanoemulsion	31
2.6.1.1	Component of Nanoemulsion	31
2.6.2	Method of Preparation of Nanoemulsion	33
2.6.2.1	High Energy Approaches	33
2.6.2.2	Low Energy Approaches	34
2.7	Nanostructured lipid carriers (NLCs) for Topical drug delivery system	37
2.7.1	Formulation of NLCs	38
2.8	References	42
Chapter 3 :Analytical Method Development		
3.1	Introduction	52
3.2	Analytical Method Validation	52
3.3	List of Material and Instruments	53
3.4	Development of Analytical Methods for Luliconazole	54
3.4.1	Luliconazole Estimation Using UV Spectrophotometry	54
3.4.1.1	Preparation of Luliconazole drug stock solution	54
3.4.1.2	Detection of λ_{max}	54
3.4.1.3	Luliconazole Calibration plot in Methanol	54
3.4.1.4	Validation method for Luliconazole by UV Spectrophotometry	54
3.4.1.4.1	Accuracy	54
3.4.1.4.2	Precision	54

3.4.1.4.3	Determination of LOD and LOQ	55
3.4.1.5	Analytical Interference study	55
3.4.2	Analytical method development of Luliconazole on HPLC	55
3.4.2.1	Mobile Phase Composition	56
3.4.2.2	Stock Solution Preparation	56
3.4.2.3	Preparation of calibration Plot	56
3.4.2.4	Sample Processing in Skin Homogenate	56
3.4.2.5	Plasma Sample Preparation	56
3.4.2.6	Validation method for Luliconazole by HPLC	57
3.4.2.6.1	Accuracy	57
3.4.2.6.2	Precision	57
3.4.2.6.3	Determination of LOD and LOQ	57
3.5	Analytical method development of Tavaborole on HPLC	57
3.5.1	Mobile Phase Composition	58
3.5.2	Stock Solution preparation	58
3.5.3	Preparation of calibration Plot	58
3.5.4	Sample Preparation in Skin Homogenate	58
3.5.5	Plasma Sample Preparation	59
3.5.6	Validation method for Tavaborole by HPLC	59
3.5.6.1	Accuracy	59
3.5.6.2	Precision	59
3.5.6.3	Determination of LOD and LOQ	59
3.6	Result and Conclusion	60
3.6.1	Determination of Luliconazole via UV Spectrophotometry	60
3.6.2	Validation of UV spectrophotometric methods for Luliconazole	62
3.6.2.1	Accuracy	62
3.6.2.2	Precision	62
3.6.3	Analytical interference Study	63
3.6.4	Estimation of Luliconazole using HPLC	63

3.6.5	Estimation of Tavaborole by HPLC method	69
3.7	References	76
Chapter 4 :Preformulation Study		
4.1	Introduction	77
4.2	Materials and Instruments	77
4.3	Methodology	78
4.3.1	Organoleptic Properties	78
4.3.2	Melting Point determination by Glass Capillary Method	78
4.3.3	Infrared Spectroscopy	78
4.3.4	Differential scanning Calorimetry (DSC)	78
4.3.5	Solubility study for selection of oil	78
4.3.6	Determining the Optimal Surfactant and Cosurfactant	79
4.3.7	Primary screening of solid lipids and surfactants	79
4.3.8	Selection of the ratio of solid lipid to liquid lipid	79
4.4	Result and Discussion	79
4.4.1	Organoleptic characterization of the drug	79
4.4.2	Determination of Melting Point	80
4.4.3	Fourier Transfer Infrared Spectroscopy (FT-IR) of Drug	80
4.4.4	Differential scanning Calorimetry (DSC)	89
4.4.5	Solubility study for selection of oil	90
4.4.6	Screening of the Surfactant and Cosurfactant	92
4.4.7	Solubility study for selection of lipid	94
4.4.8	Selection of the ratio of solid lipid to liquid lipid	95
4.5	References	96
Chapter 5 :Formulation Development and Evaluation of Nanoemulsion		
5.1	Introduction	98
5.2	Materials and Instruments	98
5.3	Methodology	99
5.3.1	Preparation of Luliconazole loaded Nanoemulsion (LZNE) and Tavaborole loaded Nanoemulsion (TBNE)	99

5.3.2	Implementing QbD for Formulation Development	99
5.3.2.1	Quality Target Product Profile (QTPP)	100
5.3.2.2	Formulation Optimization Using Box-Behnken Design (BBD)	100
5.3.2.3	Preparation of checkpoint batches as per the overlay plot	101
5.3.3	Analysis of LZNE and TBNE	101
5.3.3.1	Measurement of Globule Size, PDI, and Zeta Potential	101
5.3.3.2	Determination of %Entrapment Efficiency	101
5.3.3.3	Evaluating the Thermodynamic Stability of LZNE and TBNE	101
5.3.3.3.1	Centrifugation Analysis	102
5.3.3.3.2	Heating-Cooling Cycles	102
5.3.3.3.3	Freeze-Thaw Cycles	102
5.3.3.4	% Transmittance Measurement	102
5.3.3.5	Assay	102
5.3.3.6	Differential Scanning Calorimetry (DSC)	102
5.3.3.7	Transmission Electron Microscopy (TEM)	103
5.3.3.8	Powder X-Ray Diffraction Studies	103
5.3.4	Gel Formulation of LZNE and TBNE	103
5.3.5	Characterization of the Optimized Nanoemulsion Gels	103
5.3.5.1	Gel Viscosity	103
5.3.5.2	pH Measurement of Gel	103
5.3.5.3	Gel Spreadability	103
5.3.5.4	Assay of gel	104
5.3.5.5	Gel Strength Testing	104
5.4	Results and Discussion	105
5.4.1	Formulation development of LZNE and TBNE	105
5.4.1.1	Defining QTPP	105
5.4.1.2	Identification of independent variables and qualitative risk assessment using Ishikawa diagram	106
5.4.2	Formulation optimization by Box-Behnken Design for Luliconazole loaded Nanoemulsion	106

5.4.2.1	Effect analysis of critical variables on responses	108
5.4.2.1.1	Influence of investigated parameters on globule size	108
5.4.2.1.2	Influence of investigated parameters on % EE	118
5.4.2.2	Preparation of checkpoint batches as per the overlay plot	128
5.4.3	Formulation optimization by Box-Behnken Design for TBNE	130
5.4.3.1	Effect analysis of critical variables on responses	130
5.4.3.1.1	Influence of investigated parameters on globule size	130
5.4.3.1.2	Influence of investigated parameters on % EE	140
5.4.3.2	Preparation of checkpoint batches as per the overlay plot	151
5.4.4	Characterization of LZNE and TBNE	152
5.4.4.1	Globule size, PDI, Zeta Potential and entrapment efficiency	151
5.4.4.2	Centrifugal stability test	153
5.4.4.3	Transmittance	153
5.4.4.4	Differential scanning Calorimetry (DSC)	154
5.4.4.5	Transmission electron microscopy (TEM)	156
5.4.4.6	Powder X ray diffraction studies	158
5.4.5	Characterization of optimized Luliconazole and Tavaborole nanoemulsion based gel	159
5.4.5.1	Viscosity of gel	159
5.4.5.2	Spreadability of gel	159
5.4.5.3	pH of gel	159
5.4.5.4	Assay of gel	159
5.4.5.5	Gel Strength	160
5.5	References	162
Chapter 6 :Formulation Development and Evaluation of NLCs		
6.1	Introduction	165
6.2	Materials and Instruments	165
6.3	Methodology	166
6.3.1	Preparation of Luliconazole loaded NLCs (LZ NLCs) and Tavaborole loaded NLCs (TB NLCs)	166
6.3.2	QbD approach for the formulation development	167

6.3.2.1	Quality Target Product Profile (QTPP)	167
6.3.2.2	Optimizing Formulation using Box-Behnken Design (BBD)	167
6.3.2.3	Preparation of checkpoint batches as per the overlay plot	168
6.3.3	Characterization of NLCs containing Luliconazole and Tavorole	168
6.3.3.1	Particle Size, Polydispersity Index (PDI), and Zeta Potential	168
6.3.3.2	%Entrapment Efficiency (EE)	168
6.3.3.3	Head Space Gas Chromatography (HS-GC) Testing for residual solvent	169
6.3.3.4	Differential scanning Calorimetry (DSC)	169
6.3.3.5	Transmission Electron Microscopy (TEM)	169
6.3.3.6	Powder X-Ray Diffraction Studies	169
6.3.4	Preparation of gel of Luliconazole and Tavorole loaded NLCs	169
6.3.5	Characterization of optimized Luliconazole and Tavorole NLCs based gel	170
6.3.5.1	Viscosity of gel	170
6.3.5.2	pH of gel	170
6.3.5.3	Spreadability of gel	170
6.3.5.4	Assay	170
6.3.5.5	Gel Strength	170
6.4	Results and Discussion	171
6.4.1	Preparation of Luliconazole and Tavorole loaded NLCs	171
6.4.1.1	Defining QTPP	171
6.4.2.2	Formulation optimization by Box-Behnken Design for Luliconazole loaded NLCs	172
6.4.2.3	Effect analysis of critical variables on responses	174
6.4.2.3.1	Influence of investigated parameters on Particle size	174
6.4.2.3.2	Influence of investigated parameters on % EE	184
6.4.2.4	Preparation of checkpoint batches as per the overlay plot	194
6.4.3	Formulation optimization by Box-Behnken Design for Tavorole loaded NLCs	195
6.4.3.1	Effect analysis of critical variables on responses	196
6.4.3.1.1	Influence of investigated parameters on Particle size	196

6.4.3.1.2	Influence of investigated parameters on % EE	206
6.5.3.2	Preparation of checkpoint batches as per the overlay plot	216
6.4.4	Characterization of LZ NLCs and TB NLCs	217
6.4.4.1	Particle size, PDI, Zeta Potential and %Entrapment Efficiency	217
6.4.4.2	Head Space Gas Chromatography (HS-GC) Testing for residual solvent	218
6.4.4.3	Differential scanning Calorimetry (DSC)	221
6.4.4.4	Transmission electron microscopy (TEM)	223
6.4.4.5	Powder X ray diffraction studies	224
6.4.5	Characterization of optimized Luliconazole and Tavaborole NLCs based gel	225
6.4.5.1	Viscosity of gel	225
6.4.5.2	Spreadability of gel	225
6.4.5.3	pH of gel	225
6.4.5.4	Assay of gel	225
6.4.5.5	Gel Strength	226
6.5	References	228
Chapter 7 :<i>In-vitro</i> and Ex-vivo studies		
7.1	Introduction	232
7.2	Materials and Instruments	232
7.3	Methodology	233
7.3.1	<i>In-vitro</i> drug release	233
7.3.2	<i>In-vitro</i> cytotoxicity and cellular uptake studies	234
7.3.2.1	Cell culture handling and sub-culturing protocol	234
7.3.2.2	MTT Assay	234
7.3.2.3	Cellular uptake studies	235
7.3.3	<i>In-vitro</i> determination of minimum inhibitory concentration(MIC)	236
7.3.4	Ex-vivo characterization	236
7.3.4.1	Skin collection and preservation	236
7.3.4.2	Ex-vivo permeation and deposition study	236

7.3.4.3	Ex-vivo fluorescence microscopy study	237
7.3.4.4	Transangual Permeation Study	237
7.3.5	Anti-Fungal activity of developed formulations against <i>T. rubrum</i> by zone of inhibition method	238
7.3.6	Development of Ex-vivo onychomycosis model	238
7.3.6.1	Preparation of <i>T. rubrum</i> infected Ex- vivo Onychomycosis Model	239
7.3.6.2	Scanning Electron Microscopy	239
7.4	Results and Discussion	239
7.4.1	<i>In-vitro</i> drug release study	239
7.4.2	<i>In-vitro</i> cytotoxicity and cellular uptake studies	243
7.4.2.1	MTT assay	243
7.4.2.2	Cellular uptake studies	245
7.4.3	<i>In-vitro</i> determination of minimum inhibitory concentration (MIC)	248
7.4.4	Ex-vivo characterization	249
7.4.4.1	Ex-vivo permeation and deposition study	249
7.4.4.2	Ex-vivo fluorescence microscopy study	251
7.4.4.3	Transungual Permeation Study	255
7.4.5	Anti-microbial activity assay against <i>T. rubrum</i> by Zone of Inhibition method	258
7.4.6	Development of Ex-vivo onychomycosis model	259
7.5	Reference	274
Chapter 8 :<i>In-vivo</i> Study		
8.1	Introduction	277
8.2	Materials and Methods	277
8.2.1	Materials	277
8.2.2	Pharmacokinetic study	277
8.2.2.1	Animal study protocol approval	277
8.2.2.2	Method	277
8.3	Pharmacodynamic study	279
8.3.1	Animal study protocol approval	279

8.3.2	Method	279
8.3.3	Collection of Skin samples	280
8.4	Result and Discussion	281
8.4.1	Pharmacokinetic study	281
8.4.2	Pharmacodynamic study	283
8.5	References	294
Chapter 9 :Stability Study		
9.1	Introduction	295
9.2	Materials	295
9.3	Stability study	295
9.4	Results and Discussion	296
9.5	References	300
Chapter 10 :Summary and Conclusion		
10.1	Introduction	301
10.2	Analytical method development	301
10.3	Preformulation studies	302
10.4	Formulation development of Nanoemulsion of Luliconazole and Tavaborole	303
10.5	Characterization of Nanoemulsion of Luliconazole and Tavaborole	303
10.6	Incorporation of Nanoemulsion into gel	304
10.7	Formulation development of NLCs of Luliconazole and Tavaborole	304
10.8	Characterization of NLCs of Luliconazole and Tavaborole	304
10.9	Incorporation of NLCs into gel	305
10.10	In-vitro and ex-vivo studies	305
10.11	Stability study	306
10.12	Conclusion	306

LIST OF FIGURES

Fig. No.	Titles	Page No.
Chapter 1 : Introduction		
1.1	Classification of skin fungal infections depending upon the depth of penetration of parasitic fungus into the skin	3
1.2	Skin fungal infection	4
1.3	Types of Nail Fungal Infection	4
1.4	Drug permeation through transungual route from Microemulsion	8
1.5	Drug permeation through skin from Nanoemulsion	9
1.6	Drug permeation through skin from NLCs	10
Chapter 2 :Literature Review		
2.1	Types of fungal infection	17
2.2	Overview of skin fungal infection	19
2.3	Types of onychomycosis	20
2.4	Structure of Luliconazole	24
2.5	Structure of Tavaborole	29
2.6	Basic structure of w/o and o/w nanoemulsion	31
2.7	Composition of NLCs	38
Chapter 3 :Analytical Method Development		
3.1	UV Spectrum of Luliconazole in Methanol	60
3.2	Calibration plot of Luliconazole in Methanol	61
3.3	Interference study of drug and excipients	63
3.4	Overlay Chromatogram of Luliconazole by HPLC	64
3.5	Overlay Chromatogram of Luliconazole by HPLC in skin homogenate	64
3.6	Overlay Chromatogram of Luliconazole by HPLC in rat plasma	65
3.7	Calibration plot of Luliconazole by HPLC	66
3.8	Calibration plot of Luliconazole by HPLC (Skin Homogenate)	66
3.9	Calibration plot of Luliconazole by HPLC (Rat Plasma)	67
3.10	Overlay Chromatogram of Tavaborole by HPLC	70

3.11	Overlay Chromatogram of Tavaborole by HPLC in skin homogenate	71
3.12	Overlay Chromatogram of Tavaborole by HPLC in rat plasma	71
3.13	Calibration plot of Tavaborole by HPLC	72
3.14	Calibration plot of Tavaborole by HPLC in skin homogenate	72
3.15	Calibration plot of Tavaborole by HPLC in rat plasma	73
Chapter 4 :Preformulation Study		
4.1	Reference spectrum of Luliconazole	80
4.2	FTIR spectrum of Luliconazole	81
4.3	FTIR spectrum of physical mixture of Luliconazole and Capmul MCM C8	82
4.4	FTIR spectrum of physical mixture of Luliconazole and Coconut oil	82
4.5	FTIR spectrum of physical mixture of Luliconazole and Cremophore EL	83
4.6	FTIR spectrum of Luliconazole + Physical mixture of Capmul MCM C8, Coconut oil, Cremophore EL, Pluronic F127 (For Nanoemulsion)	83
4.7	FTIR spectrum of Luliconazole + Physical mixture of Capmul MCM C8, Softemul AS, Cremophore EL, Pluronic F127 (For NLCs)	84
4.8	Reference FTIR spectrum of Tavaborole	85
4.9	FTIR spectrum of Tavaborole	85
4.10	FTIR spectrum of physical mixture of Tavaborole and Capmul MCM C8	86
4.11	FTIR spectrum of physical mixture of Tavaborole and Coconut oil	87
4.12	FTIR spectrum of physical mixture of Tavaborole and Cremophore EL	87
4.13	FTIR spectrum of Tavaborole + Physical mixture of Capmul MCM C8, Coconut oil, Cremophore EL, Pluronic F127 (For Nanoemulsion)	88
4.14	FTIR spectrum of Tavaborole + Physical mixture of Capmul MCM C8, Softemul SE, Cremophore EL, Pluronic F127 (For NLCs)	88
4.15	DSC thermogram of Luliconazole	89
4.16	DSC thermogram of Tavaborole	90
4.17	Solubility of Luliconazole in different oils	90

4.18	Solubility of Tavaborole in different oils, liquid lipids and surfactants	91
4.19	Solubility of Luliconazole in different solid lipids and surfactants	94
4.20	Solubility of Tavaborole in different solid lipids and surfactants	95
Chapter 5 :Formulation development of Nanoemulsion		
5.1	Ishikawa diagram showing probable variables that may influence CQA	106
5.2	Actual v/s Predicted plot for % globule size	110
5.3	Contour plot (2D) showing the combined effect of Smix concentration and homogenization speed on globule size	113
5.4	Contour plot (2D) showing the combined effect of oil concentration and homogenization speed on globule size	114
5.5	Contour plot (2D) showing the combined effect of oil concentration and Smix concentration on globule size	115
5.6	Response surface (3D) showing the combined effect of Smix concentration and Oil concentration on globule size	116
5.7	Contour plot (2D) showing the combined effect of oil concentration and homogenization speed on globule size	117
5.8	Contour plot (2D) showing the combined effect of Smix concentration and homogenization speed on globule size	118
5.9	Actual v/s Predicted plot for % EE	121
5.10	Contour plot (2D) showing the combined effect of Oil concentration and Smix Concentration on % EE	123
5.11	Contour plot (2D) showing the combined effect of Oil concentration and Homogenization speed on % EE	124
5.12	Contour plot (2D) showing the combined effect of Smix concentration and Homogenization speed on % EE	125
5.13	Response surface (3D) showing the combined effect of oil concentration and Smix concentration on % EE	126
5.14	Response surface (3D) showing the combined effect of oil concentration and Homogenization speed on % EE	127
5.15	Response surface (3D) showing the combined effect of Smix concentration and Homogenization speed on % EE	128
5.16	Overlay plot of LZ NE	129
5.17	Actual v/s Predicted plot for % globule size	133
5.18	Contour plot (2D) showing the combined effect of oil concentration and Smix concentration on globule size	135
5.19	Contour plot (2D) showing the combined effect of oil concentration and homogenization speed on globule size	136
5.20	Contour plot (2D) showing the combined effect of Homogenization speed and Smix concentration on globule	137

	size	
5.21	Response surface (3D) showing the combined effect of Smix concentration and Homogenization speed on globule size	138
5.22	Response surface (3D) showing the combined effect of oil concentration and Smix concentration on globule size	139
5.23	Response surface (3D) showing the combined effect of Oil concentration and homogenization speed on globule size	140
5.24	Actual v/s Predicted plot for % EE	143
5.25	Contour plot (2D) showing the combined effect of Oil concentration and Smix Concentration on % EE	145
5.26	Contour plot (2D) showing the combined effect of Oil concentration and Homogenization speed on % EE	146
5.27	Contour plot (2D) showing the combined effect of Smix concentration and Homogenization speed on % EE	147
5.28	Response surface (3D) showing the combined effect of oil concentration and Smix concentration on % EE	148
5.29	Response surface (3D) showing the combined effect of oil concentration and Homogenization speed on % EE	149
5.30	Response surface (3D) showing the combined effect of Smix concentration and Homogenization speed on % EE	150
5.31	Overlay plot of TBNE	151
5.32	DSC graph of LZNE	154
5.33	DSC graph of TBNE	155
5.34	TEM image of LZNE	156
5.35	TEM image of TBNE	157
5.36	XRD of Luliconazole	158
5.37	XRD graph of LZNE	158
5.38	Gel strength of LZNE	160
5.39	Gel strength of TBNE	161
Chapter 6 :Formulation development of NLCs		
6.1	Ishikawa diagram showing probable variables that may influence CQA	172
6.2	Actual v/s Predicted plot for % Particle size	176
6.3	Contour plot (2D) showing the combined effect of Smix concentration and lipid concentration on Particle size	178
6.4	Contour plot (2D) showing the combined effect of lipid concentration and sonication time on Particle size	179
6.5	Contour plot (2D) showing the combined effect of sonication time and Smix concentration on Particle size	180

6.6	Response surface (3D) showing the combined effect of Smix concentration and Sonication time on Particle size	181
6.7	Contour plot (2D) showing the combined effect of lipid concentration and Smix concentration on Particle size	182
6.8	Contour plot (2D) showing the combined effect of lipid concentration and sonication time on Particle size	183
6.9	Actual v/s Predicted plot for % EE	185
6.10	Contour plot (2D) showing the combined effect of Lipid concentration and Smix Concentration on % EE	188
6.11	Contour plot (2D) showing the combined effect of Lipid concentration and Sonication time on % EE	189
6.12	Contour plot (2D) showing the combined effect of Smix concentration and Sonication time on % EE	190
6.13	Response surface (3D) showing the combined effect of sonication time and Smix concentration on % EE	191
6.14	Response surface (3D) showing the combined effect of lipid concentration and Sonication time on % EE	192
6.15	Response surface (3D) showing the combined effect of Smix concentration and Lipid concentration on % EE	193
6.16	Overlay plot for optimization of LZ NLCs	194
6.17	Actual v/s Predicted plot for % Particle size	198
6.18	Contour plot (2D) showing the combined effect of lipid concentration and Smix concentration on Particle size	200
6.19	Contour plot (2D) showing the combined effect of lipid concentration and sonication time on Particle size	201
6.20	Contour plot (2D) showing the combined effect of Sonication time and Smix concentration on Particle size	202
6.21	Response surface (3D) showing the combined effect of Smix concentration and Sonication time on Particle size	203
6.22	Contour plot (2D) showing the combined effect of lipid concentration and Smix concentration on Particle size	204
6.23	Contour plot (2D) showing the combined effect of Lipid concentration and sonication time on Particle size	205
6.24	Actual v/s Predicted plot for % EE	208
6.25	Contour plot (2D) showing the combined effect of Lipid concentration and Smix Concentration on % EE	210
6.26	Contour plot (2D) showing the combined effect of Lipid concentration and Sonication time on % EE	211
6.27	Contour plot (2D) showing the combined effect of Smix concentration and Sonication time on % EE	212
6.28	Response surface (3D) showing the combined effect of lipid concentration and Smix concentration on % EE	213
6.29	Response surface (3D) showing the combined effect of lipid	214

	concentration and Sonication time on % EE	
6.30	Response surface (3D) showing the combined effect of Smix concentration and Sonication time on % EE	215
6.31	Overlay plot of TB NLCs	216
6.32	GC chromatogram of standard (Acetone)	218
6.33	GC chromatogram of Luliconazole loaded NLCs	219
6.34	GC chromatogram of Tavaborole loaded NLCs	220
6.35	DSC graph of Luliconazole loaded NLCs	221
6.36	DSC graph of Tavaborole loaded NLCs	222
6.37	TEM image of LZ NLCs	223
6.38	TEM image of TB NLCs	223
6.39	XRD spectrum of Luliconazole	224
6.40	XRD spectrum of NLCs of Luliconazole	224
6.41	Gel strength of Luliconazole loaded NLCs	226
6.42	Gel strength of Tavaborole loaded NLCs	227
Chapter 7 : In-vitro and Ex-vivo studies		
7.1	<i>In-vitro</i> drug release study of Luliconazole loaded formulations	241
7.2	<i>In-vitro</i> drug release study of Tavaborole loaded formulations	241
7.3	<i>In-vitro</i> cell viability data for Luliconazole formulations in 3T3 fibroblast cells	244
7.4	<i>In-vitro</i> cell viability data for Tavaborole formulations in 3T3 fibroblast cell	244
7.5	<i>In-vitro</i> cell uptake of Luliconazole formulations in 3T3-fibroblast cells	246
7.6	<i>In-vitro</i> cellular uptake of Tavaborole formulations in 3T3-fibroblast cells	248
7.7	Fluorescence microscopic images of rat skin sections after 12h of treatment with A. Luliconazole gel B. Luliconazole loaded nanoemulsion based gel and C. Luliconazole loaded NLCs based gel	253
7.8	Fluorescence microscopic images of rat skin sections	255

	after 12h of treatment with A. Tavaborole gel B. Tavaborole loaded nanoemulsion based gel and C. Tavaborole loaded NLCs based gel	
7.9	Transungual Permeation study of Luliconazole loaded developed formulations	257
7.10	Transungual Permeation study of Tavaborole loaded developed formulations	257
7.11	Antifungal activity of different formulations of LZ	258
7.12	Antifungal activity of different formulations of TB	258
7.13	Sample-1 (Culture + Nail Treated with Sample-1)	259
7.14	Sample-2-(Culture + Nail Treated with Sample-2)	260
7.15	Sample-3 (Culture + Nail Treated with Sample-3)	261
7.16	Sample-4 (Culture + Nail Treated with Sample-4)	262
7.17	Sample-5 (Culture + Nail Treated with Sample-5)	263
7.18	Sample-6 (Culture + Nail Treated with Sample-6)	264
7.19	Blank Nail Treated with Sample-1	265
7.20	Blank Nail Treated with Sample-2	266
7.21	Blank Nail Treated with Sample-3	267
7.22	Blank Nail Treated with Sample-4	268
7.23	Blank Nail Treated with Sample-5	269
7.24	Blank Nail Treated with Sample-6	270
7.25	Blank Nail	271
7.26	Nail culture control	272
Chapter 8 :In-vivo Study		
8.1	Plasma drug concentration of Luliconazole after applying various formulation of Luliconazole	282
8.2	Plasma drug concentration of Tavaborole after applying various formulation of Tavaborole	283
8.3	Effect of model control on clinical signs of fungal infection	284
8.4	Effect of nanoemulgel placebo test control on clinical signs of fungal infection	285
8.5	Effect of standard control (1% w/w luzu gel) on clinical signs of fungal infection	286

8.6	Effect of 1% w/w LZ nanoemulgel on clinical signs of fungal infection	287
8.7	Effect of 1% w/w LZ NLCs based gel on clinical signs of fungal infection	288
8.8	Effect of marketed formulation of TB on clinical signs of fungal infection	289
8.9	Effect of nanoemulgel of TB on clinical signs of fungal infection	290
8.10	Effect of NLCs based gel of TB on clinical signs of fungal infection	291
8.11	Effect of nano formulation on skin structural alterations induced by fungal infection (H& E stain, all images were captured at 10X magnification and scale bar was 100 pixels.	294
Chapter 9: Stability Study		
9.1	Effect on globule/particle size of Luliconazole formulations during stability studies	297
9.2	Effect on zeta potential of Luliconazole formulations during stability studies	297
9.3	Effect on %EE of Luliconazole formulations during stability studies	298
9.4	Effect on globule/particle size of Tavaborole formulations during stability studies	298
9.5	Effect on zeta potential of Tavaborole formulations during stability studies	299
9.6	Effect on %EE of Tavaborole formulations during stability studies	299

LIST OF TABLES

Table No.	Titles	Page No.
Chapter 2 :Literature Review		
2.1	Review of work done on Luliconazole	25
2.2	Review of work done on Tavaborole	30
2.3	Examples of surfactant	32
2.4	Literature review of nanoemulsion for topical drug delivery system	35
2.5	Literature review of NLCs for topical drug delivery system	39
Chapter 3 :Analytical Method Development		
3.1	Analytical techniques reported for Tavaborole and Luliconazole	53
3.2	List of Materials	53
3.3	List of Instruments	53
3.4	HPLC process parameters	55
3.5	Analytical method development of Tavaborole on HPLC	57
3.6	Calibration data for estimation of Luliconazole in Methanol	60
3.7	Parameters from calibration plot of Luliconazole in Methanol	61
3.8	Accuracy in methanol	62
3.9	Intraday and interday precision analysis of Luliconazole	62
3.10	Drug Excipients interference study	63
3.11	Data of Calibration plot in Methanol:Water:ACN (75:25:10)	65
3.12	Parameters from calibration plots	67
3.13	Accuracy of the method	68
3.14	Intraday and interday precision analysis of Luliconazole	68
3.15	Data of Calibration plot in OPA:ACN (60:40)	69
3.16	Parameters from calibration plot	73
3.17	Accuracy of the method	74
3.18	Intraday and interday precision analysis of Tavaborole	75
Chapter 4 :Preformulation Study		
4.1	List of Materials	77

4.2	List of Equipments	77
4.3	Organoleptic characterization of the drug	79
4.4	Observed Melting Point	80
4.5	Interpretation of FTIR of Luliconazole	81
4.6	FTIR Interpretation of Tavaborole	86
4.7	Screening of Surfactant and Cosurfactant	92
Chapter 5 :Formulation Development and Evaluation of Nanoemulsion		
5.1	List of Materials	98
5.2	List of Equipments	99
5.3	Selected values of variables for BBD	100
5.4	QTPP and CQA elements with justification for LZNE	105
5.5	Randomized BBD design matrix generated Design-Expert software	107
5.6	Statistical analysis of design for Globule size	108
5.7	ANOVA for Response Surface Quadratic Model for globule size	108
5.8	ANOVA study results for globule size	110
5.9	The Final equation in terms of actual factors	111
5.10	Statistical analysis of design for % EE	119
5.11	ANOVA for Response Surface Quadratic Model for % EE	119
5.12	ANOVA study results for % EE	121
5.13	The Final equation in terms of actual factors	122
5.14	Results of check point batch and optimized batch for globule size and % EE	129
5.15	Randomized BBD design matrix generated Design-Expert software	130
5.16	Statistical analysis of design for Globule size	131
5.17	ANOVA for Response Surface Quadratic Model for globule size	131
5.18	ANOVA study results for globule size	133
5.19	The Final equation in terms of actual factors	134
5.20	Statistical analysis of design for % EE	140
5.21	ANOVA for Response Surface Quadratic Model for % EE	141

5.22	ANOVA study results for % EE	143
5.23	The Final equation in terms of actual factors	144
5.24	Results of check point batches for globule size and % EE	151
5.25	Composition of optimized batch of LZNE loaded gel and TBNE loaded gel	152
Chapter 6 :Formulation Development and Evaluation of NLCs		
6.1	List of Materials	165
6.2	List of Equipments	166
6.3	Selected values of variables for BBD	167
6.4	QTPP and CQA elements with justification for LZ NLCs	171
6.5	Randomized BBD design matrix generated Design-Expert software	173
6.6	Statistical analysis of design for Particle size	174
6.7	ANOVA for Response Surface Quadratic Model for Particle size	174
6.8	ANOVA study results for Particle size	176
6.9	The Final equation in terms of actual factors	177
6.10	Statistical analysis of design for % EE	184
6.11	ANOVA for Response Surface Quadratic Model for % EE	184
6.12	ANOVA study results for % EE	186
6.13	The Final equation in terms of actual factors	186
6.14	Results of check point batch and optimized batch for particle size and %entrapment efficiency	195
6.15	Randomized BBD design matrix generated Design-Expert software	195
6.16	Statistical analysis of design for Particle size	196
6.17	ANOVA for Response Surface Quadratic Model for Particle size	197
6.18	ANOVA study results for Particle size	198
6.19	The Final equation in terms of actual factors	199
6.20	Statistical analysis of design for % EE	206
6.21	ANOVA for Response Surface Quadratic Model for % EE	206
6.22	ANOVA study results for % EE	208
6.23	The Final equation in terms of actual factors	209

6.24	Results of check point batch and optimized batch for particle size and %entrapment efficiency	216
6.25	Composition of optimized batch of LZ NLCs loaded gel and TB NLCs loaded gel	217
Chapter 7 : <i>In-Vitro</i> and Ex-vivo Studies		
7.1	List of Materials and Reagents	232
7.2	List of Equipments	233
7.3	List of Sample code and sample name	238
7.4	<i>In-vitro</i> drug release study of Luliconazole loaded formulations	239
7.5	<i>In-vitro</i> drug release study of Tavaborole loaded formulations	240
7.6	Various mathematical models and their correlation coefficient (R^2) values	242
7.7	<i>In-vitro</i> cell viability data for Luliconazole and Tavaborole loaded formulations in 3T3 fibroblast cells	243
7.8	MIC values of developed formulations of Luliconazole and Tavaborole against <i>Candida albicans</i> and <i>Trichophyton rubrum</i>	248
7.9	Ex-vivo drug release study of Luliconazole loaded formulations	249
7.10	Ex-vivo drug release study of Tavaborole loaded formulations	250
7.11	Ex-vivo Drug release from developed formulations of Luliconazole and Tavaborole	250
7.12	Transungual Permeation by Luliconazole loaded formulations	255
7.13	Transungual Permeation by Tavaborole loaded formulations	256
Chapter 8 : <i>In-vivo</i> Study		
8.1	Animal grouping for pharmacokinetic study	278
8.2	Animal grouping for pharmacodynamic study	280
8.3	Plasma drug concentration of Luliconazole after applying various formulation of Luliconazole	281
8.4	Plasma drug concentration of Tavaborole after applying various formulation of Tavaborole	282
Chapter 9 :Stability Study		
9.1	Stability study of Luliconazole and Tavaborole loaded developed formulations at storage condition $30\pm 2^\circ\text{C}/65\pm 5\%\text{RH}$	296